HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cosmetics international trade

This article was originally published in The Rose Sheet

Executive Summary

Korean Cosmetic Products Act pointed to as trade concern by U.S. Trade Representative in 2001 Annual Report released March 19. "U.S. government has repeatedly raised its concerns with Korea," and both the U.S. and EU "are considering next steps to resolve this issue," USTR says. New regs are "extremely vague," USTR asserts, noting only 18 U.S. products have been approved for sale out of more than 600 applications. Cosmetic Products Act, which went into effect July 2000, applies pharmaceutical-type standards to some cosmetic products such as skin whiteners and sunscreens. Cosmetic, Toiletry and Fragrance Association testified before the International Trade Committee against the regulations last year as part of a general fact-finding investigation (1"The Rose Sheet" June 11, 2001, p. 6)...

You may also be interested in...

Korean "Cosmeceutical" Regs Impede Free Trade Agreement - CTFA

Applying pharmaceutical-type standards to cosmetic products creates a barrier for U.S. cosmetic companies marketing in the Republic of Korea, CTFA VP-International Louis Santucci asserts in written testimony to the International Trade Commission.

India’s Draft Guidelines For COVID-19 Vaccines Follow WHO, US Lead

India has rolled out draft guidelines for development of vaccines with special focus on COVID-19 vaccines, drawing from those of other regulatory bodies and the WHO. Experts suggest the primary efficacy endpoint of minimum 50% is acceptable given that vaccines against respiratory diseases are difficult to develop though not necessarily enough to snuff out a pandemic.

Akero Looks To Accelerate Path To Pivotal NASH Data With Phase IIb/III Protocol

Akero gets FDA’s ok to conduct Phase IIb/III study of FGF21 analog efruxifermin in biopsy-confirmed non-alcoholic steatohepatitis patients. With NASH leadership up in the air, Akero, 89bio and other FGF analog sponsors jockey for top spot.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts